This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

Pyrotinib in Combination With Capecitabine in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04001621
Recruitment Status : Active, not recruiting
First Posted : June 28, 2019
Last Update Posted : December 8, 2022
Information provided by (Responsible Party):
Xichun Hu, Fudan University

Brief Summary:
Trastuzumab resistance, which is a common therapeutic challenge in HER2 positive metastatic breast cancer, is not fully understood. Pyrotinib is an oral tyrosine kinase inhibitor targeting EGFR, HER-2 and HER-4 receptors. More general inhibition of ErbB family with pyrotinib could provide additional benefit. This study is designed to evaluate the efficacy and safety of pyrotinib in combination with capecitabine in patients with HER2 positive locally advanced or metastatic breast cancer who had early failure on or after trastuzumab treatment.

Condition or disease Intervention/treatment Phase
Metastatic Breast Cancer Drug: Pyrotinib combined with capecitabine Phase 2

Detailed Description:
A multi-center, one-arm, open label design study, which is planned to enroll 100 patients with trastuzumab-resistant HER2-positive advanced breast cancer.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Pyrotinib in Combination With Capecitabine in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer
Actual Study Start Date : June 26, 2019
Estimated Primary Completion Date : May 31, 2023
Estimated Study Completion Date : December 31, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Pyrotinib plus capecitabine
pyrotinib(400 mg once daily) + capecitabine (2000 mg/m^2 daily, 1000 mg/m^2 BID)
Drug: Pyrotinib combined with capecitabine
pyrotinib 400 mg once daily; Capecitabine 1000 mg/m2 per day on day 1 through 14, every 21 days.

Primary Outcome Measures :
  1. Progression Free Survival (PFS) [ Time Frame: Estimated 12 months ]
    From enrollment to progression or death (for any reason)

Secondary Outcome Measures :
  1. Objective Response Rate (ORR) [ Time Frame: Estimated 12 months ]
    Ratio of CR and PR in all subjects

  2. Duration of Response (DOR) [ Time Frame: Estimated 12 months ]
    The first evaluation of CR or PR to progression or death (for any reason)

  3. Clinical Benefit rate (CBR) [ Time Frame: Estimated 12 months ]
    Ratio of CR,PR and SD greater than or equal to 24 weeks in all subjects

  4. Overall Survival (OS) [ Time Frame: Estimated 24 months ]
    From enrollment to death (for any reason)

  5. Adverse Events and Serious Adverse Events [ Time Frame: From informed consent through 28 days following treatment completion ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Pathologically confirmed HER2 positive patients with locally advanced or metastatic breast cancer: HER2 IHC 3+, or HER2 IHC 2+ and FISH detection gene amplification
  2. Aged ≥18 and ≤70 years.
  3. ECOG performance status of 0 to 1.
  4. Life expectancy of more than 12 weeks;
  5. At least one measurable lesion exists(RECIST 1.1)
  6. Patients with trastuzumab resistance is defined as follows:

    Progression during or within 12 months after treatment in neoadjuvant or adjuvant setting (at least 9 weeks of trastuzumab treatment); Or Progression during or within 6 months after treatment for locally advanced or metastatic disease in the first-line setting (at least 6 weeks of trastuzumab treatment).

  7. At least 4 weeks from the last treatment of trastuzumab or chemotherapy,at least 5 times of t1/2 or 4 weeks from the last treatment of endocrine therapy(the shorter one is preferred)
  8. Known hormone receptor status
  9. For patients with brain metastases, local treatment (including whole cranial radiotherapy, SBRT, etc.) is required and the brain lesions are stable for ≥ 3 months without the need for dexamethasone or mannitol treatment
  10. Patients with adequate organ function before enrollment:

    1. ANC≥1.5×10^9/L
    2. PLT≥100×10^9/L
    3. Hb≥90 g/L
    4. TBIL≤1.5×ULN
    5. ALT and AST≤3×ULN, (ALT and AST≤5×ULN in patients with liver metastases)
    6. Cr≤1.5×ULN and the creatinine clearance rate≥50 mL/min
    7. LVEF ≥ 50%
    8. QTcF < 480 ms
  11. Signed informed consent.

Exclusion Criteria:

  1. Patients with meningeal metastasis and / or spinal cord metastasis;
  2. Patients unable to swallow, with chronic diarrhea, intestinal obstruction, or multiple factors that affect drug use and absorption;
  3. Patients with malignant serious effusion which cannot be controlled by drainage or other methods;
  4. Less than 4 weeks from the last treatment in last clinical trial;
  5. Known dihydropyrimidine dehydrogenase (DPD) deficiency;
  6. Receiving any other antitumor therapy;
  7. History of other malignancy within the last 5 years, except for carcinoma in situ of cervix, basal cell carcinoma or squamous cell carcinoma of the skin that has been previously treated with curative intent;
  8. Received radiotherapy, surgery (excluding local puncture) within 4 weeks prior to enrollment; received anti-tumor endocrine therapy after entering the screening period;
  9. Previous or ongoing use of HER2-targeted tyrosine kinase inhibitors (lapatinib, neratinib or pyrotinib);
  10. Previous use of capecitabine or capecitabine not tolerated, except that capecitabine efficacy cannot be judged or capecitabine discontinuation for 3 months or more;
  11. Patients with serious heart disease;
  12. Allergy to pyrotinib; history of immunodeficiency, including HIV positive, active HBV/HCV or other acquired, congenital immunodeficiency disease, or organ transplantation history;
  13. Known history of neurological or psychiatric disease, including epilepsy or dementia;
  14. Patients during pregnancy or lactation, patients with childbearing potential tested positive in baseline pregnancy test, or patients unwilling to take effective contraceptive measures throughout the trial;
  15. Evidence of significant medical illness that will substantially increase the risk on the participation or completion of the study in the investigator's judgment. Examples included, but not limited to, hypertension, severe diabetes, etc;
  16. Patients not eligible for this study judged by the investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04001621

Layout table for location information
Fudan University Shanghai Cancer Center
Shanghai, China, 200032
Sponsors and Collaborators
Fudan University
Layout table for investigator information
Principal Investigator: Xichun Hu Department of Oncology
Layout table for additonal information
Responsible Party: Xichun Hu, professor, Fudan University Identifier: NCT04001621    
Other Study ID Numbers: HR-BLTN-003
First Posted: June 28, 2019    Key Record Dates
Last Update Posted: December 8, 2022
Last Verified: December 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents